A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

602

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GW642444 6.25

GW642444 6.25

DRUG

GW642444 3mcg

once daily

DRUG

GW642444 12.5mcg

GW642444 12.5mcg

DRUG

GW642444 25mcg

GW642444 25mcg

DRUG

GW642444 50mcg

GW642444 50mcg

OTHER

placebo

placebo

Trial Locations (99)

1000

GSK Investigational Site, Manila

1101

GSK Investigational Site, Quezon City

2650

GSK Investigational Site, Hvidovre

2900

GSK Investigational Site, Hellerup

4217

GSK Investigational Site, Lipa City

5000

GSK Investigational Site, Odense C

10538

GSK Investigational Site, Larchmont

11550

GSK Investigational Site, México

13419

GSK Investigational Site, Tallinn

13619

GSK Investigational Site, Tallinn

14057

GSK Investigational Site, Berlin

14901

GSK Investigational Site, Elmira

15562

GSK Investigational Site, Rüdersdorf

19140

GSK Investigational Site, Philadelphia

19713

GSK Investigational Site, Newark

21502

GSK Investigational Site, Geesthacht

23225

GSK Investigational Site, Richmond

24210

GSK Investigational Site, Abingdon

27607

GSK Investigational Site, Raleigh

27834

GSK Investigational Site, Greenville

28207

GSK Investigational Site, Charlotte

28625

GSK Investigational Site, Statesville

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

30060

GSK Investigational Site, Marietta

32720

GSK Investigational Site, DeLand

33136

GSK Investigational Site, Miami

33511

GSK Investigational Site, Brandon

33613

GSK Investigational Site, Tampa

35501

GSK Investigational Site, Jasper

35630

GSK Investigational Site, Florence

36109

GSK Investigational Site, Montgomery

39112

GSK Investigational Site, Magdeburg

45040

GSK Investigational Site, Zapopan

45231

GSK Investigational Site, Cincinnati

46032

GSK Investigational Site, Carmel

46515

GSK Investigational Site, Elkhart

47150

GSK Investigational Site, New Albany

48152

GSK Investigational Site, Livonia

51014

GSK Investigational Site, Tartu

59701

GSK Investigational Site, Butte

63122

GSK Investigational Site, St Louis

63141

GSK Investigational Site, St Louis

63301

GSK Investigational Site, Saint Charles

64718

GSK Investigational Site, Monterrey NL

70503

GSK Investigational Site, Lafayette

70584

GSK Investigational Site, Sunset

75110

GSK Investigational Site, Corsicana

75216

GSK Investigational Site, Dallas

76712

GSK Investigational Site, Waco

77030

GSK Investigational Site, Houston

80539

GSK Investigational Site, Munich

86899

GSK Investigational Site, Landsberg am Lech

90712

GSK Investigational Site, Lakewood

91343

GSK Investigational Site, Sepuldeva

91786

GSK Investigational Site, Upland

92270

GSK Investigational Site, Rancho Mirage

92835

GSK Investigational Site, Fullerton

97220

GSK Investigational Site, Portland

97504

GSK Investigational Site, Medford

105077

GSK Investigational Site, Moscow

125315

GSK Investigational Site, Moscow

214001

GSK Investigational Site, Smolensk

410053

GSK Investigational Site, Saratov

443079

GSK Investigational Site, Samara

620109

GSK Investigational Site, Yekaterinburg

2341131

GSK Investigational Site, Valparaíso

7500551

GSK Investigational Site, Santiago

90095-1752

GSK Investigational Site, Los Angeles

48201-2018

GSK Investigational Site, Detroit

07091

GSK Investigational Site, Summit

29406-7108

GSK Investigational Site, Charleston

05403

GSK Investigational Site, South Burlington

B1602DOH

GSK Investigational Site, Vicente López

M5500CCG

GSK Investigational Site, Mendoza

C1121ABE

GSK Investigational Site, Buenos Aires

E2A 4X7

GSK Investigational Site, Bathurst

L6T 3T1

GSK Investigational Site, Brampton

S7N 0W8

GSK Investigational Site, Saskatoon

M5G 1N8

GSK Investigational Site, Toronto

J8Y 6S8

GSK Investigational Site, Gatineau

H3H 2R9

GSK Investigational Site, Montreal

04103

GSK Investigational Site, Leipzig

04626

GSK Investigational Site, Schmölln

06720

GSK Investigational Site, Mexico City

Lima 1

GSK Investigational Site, Lima

Lima 27

GSK Investigational Site, San Isidro

97-540

GSK Investigational Site, Gidle

82-550

GSK Investigational Site, Prabuty

01-138

GSK Investigational Site, Warsaw

02-097

GSK Investigational Site, Warsaw

41-803

GSK Investigational Site, Zabrze

821 06

GSK Investigational Site, Bratislava

052 01

GSK Investigational Site, Spišská Nová Ves

927 01

GSK Investigational Site, Šaľa

135-710

GSK Investigational Site, Seoul

152-703

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00606684 - A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter